<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697940</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-058</org_study_id>
    <nct_id>NCT04697940</nct_id>
  </id_info>
  <brief_title>Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL</brief_title>
  <official_title>Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Treatment in Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Han weidong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase 1/2 study has the primary objective of decitabine-primed tandem&#xD;
      CART 19/20 in patients with B-NHL who were confirmed as r/r B cell Non-Hodgkin's Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I dose escalation (3+3) : dose 1 (0.5 × 10^6 cells per kg) dose 2 (2 × 10^6 cells per&#xD;
      kg) dose 3 (5 × 10^6 cells per kg)&#xD;
&#xD;
      Phase II Appropriate dose&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety in phase I</measure>
    <time_frame>3 month</time_frame>
    <description>Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best objective Response Rate</measure>
    <time_frame>12 month</time_frame>
    <description>the incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as best response to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 month</time_frame>
    <description>PFS is defined as the time from the CAR T cells infusion date to the date of disease progression or death any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>12 month</time_frame>
    <description>DOR for subjects who experience an objective response, DOR is defined as the date of their first objective response (which is subsequently confirmed) to disease progression for r/r B-NHL or death regardless of cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 month</time_frame>
    <description>OS is defined as the time from CAR T cells infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory research:Track CAR T cells in patients after infusion using TCR, transcriptional, and epigenetic sequencing.</measure>
    <time_frame>14-28 days after infusion</time_frame>
    <description>Analysis of CAR T cell populations from patients using single-cell sequencing to distinct subtypes and clonal expansion of infiltrating lymphocytes.&#xD;
By means of the transcriptional profiles of these individual cells, coupled with assembled T cell receptor (TCR) sequences to identify CAR T cell subsets based on their molecular and functional properties.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Relapase and Refractory B-cell Non-Hodgkin's Lymphoma</condition>
  <condition>Decitabine-primed Tandem CD19/CD20 CAR T Cells</condition>
  <arm_group>
    <arm_group_label>Refractory or Relapsed Non-Hodgkin's Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine-primed Tandem CAR19/20 engineered T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Decitabine-primed Tandem CAR19/20 engineered T cells</intervention_name>
    <description>Tandem dual Specificity targeting CD19 and CD20 decitabine-primed CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 and improve the possibility of killing lymphoma tumor cells.</description>
    <arm_group_label>Refractory or Relapsed Non-Hodgkin's Lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients eligible for inclusion in this study had to meet all of the following criteria:&#xD;
&#xD;
          -  Age ≥16 and ≤70 years.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 2.&#xD;
&#xD;
          -  Histologically confirmed CD20+ and/or CD19+ B-cell non-Hodgkin lymphoma (NHL),&#xD;
             including the following types defined by the World Health Organization (WHO) 2008:&#xD;
             Diffuse large B-cell lymphoma (DLBCL) not otherwise specified, Primary mediastinal&#xD;
             large B-cell lymphoma (PMBCL), Transformed follicular lymphoma (tFL), FL, Some&#xD;
             indolent lymphomas including mantle-cell lymphoma (MCL) and chronic lymphocytic&#xD;
             leukaemia/small lymphocytic lymphoma (CLL/SLL), Mucosa associated lymphoid tissue&#xD;
             (MALT), Others.&#xD;
&#xD;
          -  Refractory disease or relapse after treatment with ≥2 lines of chemotherapy, including&#xD;
             rituximab and anthracycline and either having failed autologous hematopoietic stem&#xD;
             cell transplantation (HSCT), being ineligible for autologous HSCT or not consenting to&#xD;
             autologous HSCT.&#xD;
&#xD;
          -  Failure following autologous HSCT was defined as follows: PD or relapsed disease ≤12&#xD;
             months after autologous stem cell transplantation (ASCT) (requires biopsy-proven&#xD;
             recurrence in relapsed subjects). No response or relapse after salvage therapy is&#xD;
             given post-ASCT.&#xD;
&#xD;
          -  PD or relapse ≥3 months after treatment with targeted CD19 therapy, including CD19 CAR&#xD;
             T cells or anti-CD19/anti-CD3.&#xD;
&#xD;
          -  Successful leukapheresis assessment and preculture of T cells.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Adequate organ function:Creatinine &lt; 1.6 mg/dL (140 µmol/L) or creatinine clearance&#xD;
             ≥60 mL/min, Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) &lt; 3× upper&#xD;
             limit of the normal range, Bilirubin &lt;2.0 mg/dL unless the subject had Gilbert's&#xD;
             syndrome (&lt;3.0 mg/dL), A minimum level of pulmonary reserve defined as ≤ grade 1&#xD;
             dyspnoea and pulse oxygenation &gt; 91% with room air, Cardiac ejection fraction ≥50%, no&#xD;
             evidence of pericardial effusion as determined by an echocardiogram (ECHO), and no&#xD;
             clinically significant electrocardiogram (ECG) findings.&#xD;
&#xD;
          -  An adequate bone marrow reserve defined as: Absolute neutrophil count (ANC)&gt;1,000/mm3,&#xD;
             Absolute lymphocyte count (ALC)≥300/mm3, Platelet count ≥ 50,000/mm3, Haemoglobin &gt;&#xD;
             7.0 mg/dL.&#xD;
&#xD;
          -  Measurable or assessable disease according to the &quot;IWG Response Criteria for Malignant&#xD;
             Lymphoma&quot; (Cheson 2014). Patients in complete remission (CR) with no evidence of&#xD;
             disease were not eligible.&#xD;
&#xD;
          -  Informed consent/assent requiring that all patients have the ability to understand and&#xD;
             the willingness to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients eligible for this study must not meet any of the following criteria:&#xD;
&#xD;
          -  Patients with definite involvement of the gastrointestinal tract. Endoscopy should be&#xD;
             performed to confirm gastrointestinal involvement in suspected patients. However,&#xD;
             patients with central nervous system (CNS) involvement were cautiously enrolled in&#xD;
             this clinical study.&#xD;
&#xD;
          -  Detection of a clear HAMA effect in patients with prior CD19 CAR T cell treatment&#xD;
             failure or recurrence, or negative tumour puncture detection of CD19 and CD20.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Uncontrolled active bacterial or viral infection (active hepatitis B or hepatitis C&#xD;
             infection, HIV infection) or treponema pallidum infection.&#xD;
&#xD;
          -  Class III/IV cardiovascular disability according to the New York Heart Association&#xD;
             Classification and a cardiac ejection fraction &lt;45%.&#xD;
&#xD;
          -  History of allogeneic stem cell transplantation.&#xD;
&#xD;
          -  Requirement for urgent therapy due to tumor mass effects such as respiratory&#xD;
             obstruction or blood vessel compression.&#xD;
&#xD;
          -  Current or expected need for systemic corticosteroid therapy.&#xD;
&#xD;
          -  Any organ failure.&#xD;
&#xD;
          -  Patients with a second tumor requiring therapy or intervention.&#xD;
&#xD;
          -  Subjects considered unlikely to complete all protocol-required study visits or&#xD;
             procedures, including follow-up visits, or comply with the study requirements for&#xD;
             participation according to the investigator's judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weidong Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weidong Han, M.D.</last_name>
    <phone>+861055499341</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Han, M.D</last_name>
      <phone>+86-10-66937463</phone>
      <email>hanwdrsw@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yajing Zhang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhiqiang Wu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingming Yang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chuan Tong, M.S</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunmeng Wang, M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianshu Wei, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dongdong Ti, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deyun Chen, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

